DWTX Dogwood enrolls first 200 patients in ongoing halneuron® phase 2B chemotherapy induced neuropathy trial; top-line data expected in fall
DWTX Dogwood enrolls first 200 patients in ongoing halneuron® phase 2B chemotherapy induced neuropathy trial; top-line data expected in fall 2026
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.